Giuseppe Andò: P2Y12 Inhibition in Diabetes – A Personalized Approach
Giuseppe Andò, Head of the Cardiology Department at Papardo University Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Cardiovascular Diabetology, adding:
“New publication in Cardiovascular Diabetology!
P2Y12 inhibition in diabetes across the acute-to-chronic coronary syndrome continuum: toward a personalized antiplatelet strategy.
Diabetes increases thrombotic risk, but antiplatelet intensity should not be one-size-fits-all.
We review the evidence across ACS to CCS and discuss how ischemic/bleeding risk, PCI complexity, comorbidities and other patient characteristics should guide P2Y12-based therapy.”
Title: P2Y12 inhibition in diabetes across the acute-to-chronic coronary syndrome continuum: toward a personalized antiplatelet strategy
Authors: Lucio Giuseppe Granata, Marcello Marchetta, Pierre Sabouret, Andrea Muscarà, Giuseppina Tiziana Russo, Giuseppe Andò

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?